



HOUSE COMMITTEE ON WAYS & MEANS

CHAIRMAN RICHARD E. NEAL

KEY DRUG PRICING FACTS FOR CT-01 (REP. LARSON)

Know Your District

In CT-01, there are **112,840 people enrolled in a Medicare Part D plan** and **500,959 people enrolled in private health insurance** – all of whom stand to benefit from the passage of *H.R. 3 The Lower Drug Costs Now Act*.

Source of Prescription Drug Coverage	CT-01 Residents	
Medicare Prescription Drug Plan (PDP)	7.7%	(54,506 People)
Medicare Advantage Prescription Drug (MA-PD)	8.2%	(58,320 People)
Medicare Part D (Any Plan)	16.0%	(112,840 People)
Private Health Insurance	71.1%	(500,959 People)

Source: Committee tabulations of U.S. Census Bureau, 2017 American Community Survey 1-year estimates

Note: Some insurance categories include people who have multiple sources of coverage. Some insurance categories are not included. Therefore, totals will not sum up to 100%.

Cancer Medications

There are an estimated **15 million Americans living with cancer**, including **228,000 people in Connecticut**. Last year, over **600,000 people nationwide died of cancer**. Most new cancer medications cost patients **over \$100,000 annually** in the U.S., which is why 90 percent of Americans say cancer drugs are too expensive.

BREAST CANCER

In Connecticut, there are
48,000 women living with breast cancer

H.R. 3 can lower the average total cost of the breast cancer medication Ibrance by 189% from **\$69,000 to \$23,900 per year**.

Source: Committee tabulations of National Cancer Institute, 2016 State Cancer Profiles and 2018 pharmaceutical price data from recognized price sources.

LEUKEMIA

In Connecticut, between 2012 and 2016, there were
512 new cases of leukemia

H.R. 3 can lower the average total cost of the leukemia medication Tasigna by 243% from **\$93,700 to \$27,400 per year**.

Source: Committee tabulations of National Cancer Institute, 2016 State Cancer Profiles, and 2018 pharmaceutical price data from recognized price sources.

PROSTATE CANCER

In Connecticut, between 2012 and 2016, there were
3,880 new cases of prostate cancer

H.R. 3 can lower the average total cost of the prostate cancer medication Zytiga by 193% from **\$109,500 to \$37,400 per year**.

Source: Committee tabulations of National Cancer Institute, 2016 State Cancer Profiles, and 2018 pharmaceutical price data from recognized price sources.



H.R. 3 will Reduce Drug Costs for Millions of Americans

ARTHRITIS

22% of Connecticut residents have arthritis, 26% of whom experience severe joint pain because of it. H.R. 3 can lower their total costs on most arthritis drugs from about **\$40,000 to \$10,000 per year**.

Source: Arthritis Foundation, Committee tabulations of 2018 pharmaceutical price data from recognized price sources.

ASTHMA

11% or about 300,000 Connecticut residents live with asthma. H.R. 3 can lower their total costs on most asthma drugs from about **\$1,400 to \$270 per year**.

Source: Centers for Disease Control and Prevention, Committee tabulations of 2018 pharmaceutical price data from recognized price sources.

HIV/AIDS

270 Connecticut residents were diagnosed with HIV in 2015, ranking the state 29th nationally in HIV diagnoses. H.R. 3 can lower their total costs on most HIV drugs from about **\$15,000 to \$6,000 per year**.

Source: Centers for Disease Control and Prevention, Committee tabulations of 2018 pharmaceutical price data from recognized price sources.

MULTIPLE SCLEROSIS

One million people are living with Multiple Sclerosis (MS) in the United States. H.R. 3 can lower their total costs on most MS drugs from about **\$40,000 to \$13,000 per year**.

Source: MS Society, Committee tabulations of 2018 pharmaceutical price data from recognized price sources.

Insulin

30.3 million Americans live with diabetes, including **347,000 people in Connecticut**. Over the past decade, the price of insulin has **increased 197 percent**, and Medicare Part D spending on insulin has **increased 840 percent**.

DIABETES in CONNECTICUT

In Connecticut, there are an estimated **347,000 people living with diabetes**.

Nearly 10% of Connecticut residents live with diabetes.

Source: Committee tabulations of Center for Disease Control and Prevention, 2017 Diagnosed Diabetes Statistics, and 2018 pharmaceutical price data from recognized price sources.

INSULIN COSTS in CONNECTICUT

For the most commonly used insulin medications, Connecticut residents spend anywhere from **\$1,200 to \$20,000 annually**.

H.R. 3 can lower the average total cost of the insulin NovoLOG Flexpen by 312% from about **\$19,800 to \$4,800 per year**.

Under H.R. 3, Connecticut residents could spend **3.5 times less on insulin**.

Under H.R. 3, some commonly used insulins can cost as little as **\$400 per year**.

Source: Committee tabulations of 2018 pharmaceutical price data from recognized price sources.